Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-15. (Cancelled)

16. (Currently amended) A compound of formula (1):

wherein

is a single bond;

A is phenylene;

n is 1;

R¹ is hydrogen;

R² is hydrogen;

 R^3 is selected from C_{1-4} alkyl optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon, cyano C_{1-4} alkyl, and C_{1-4} alkyl substituted by 1 or 2 R^8 groups provided that when there are 2 R^8 groups they are not substituents on the same carbon;

 R^8 is independently selected from hydroxy, heterocyclyl, C_{1-4} alkanoyl, C_{1-4} alkanoyl, C_{1-4} alkanesulfinyl, C_{1-4} alkanesulfonyl, C_{0} 0R 9 0, $(R^9)(R^{10})NCO-$, $COCH_2OR^{11}$, $(R^9)(R^{10})N-$, $COCOR^9$ and 2,2-dimethyl-1,3-dioxolan-4-yl;

 R^9 and R^{10} are independently selected from hydrogen, hydroxy, C_{1-4} alkyl optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon and C_{1-4} alkyl substituted by C_{1-4} alkoxy and wherein R^9 and R^{10} can together with the nitrogen to which they are attached form 4- to 6-membered ring where the ring is optionally substituted on carbon by 1 or 2 substituents selected from hydroxy or carboxy;

R¹¹ is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy and hydroxyC₁₋₄alkyl; m is 1;

Application No. 10/506,748 Amendment Dated 09/18/2006 Reply to Office Action of 05/22/2006

R⁴ is chloro;

is a single or double bond;

A is phenylene or heteroarylene;

m is 1;

n is 0, 1, or 2;

 R^4 -is independently selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, $N-C_{1-4}$ alkylcarbamoyl, $N,N-(C_{1-4}$ alkyl) $_2$ carbamoyl, sulphamoyl, $N-C_{1-4}$ alkylsulphamoyl, $N,N-(C_{1-4}$ alkyl) $_2$ sulphamoyl, $-S(O)_bC_{1-4}$ alkyl (wherein b is 0, 1, or 2), C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, hydroxy C_{1-4} alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, and trifluoromethoxy; or

when n is 2, the two R⁴ groups, together with the carbon atoms of A to which they are attached, may form a 4- to 7-membered ring, optionally containing 1 or 2 heteroatoms independently selected from O, S, and N, and optionally being substituted with one or two methyl groups; R⁴ is chloro;

R² is hydrogen, hydroxy, or carboxy;

 R^3 -is selected from hydrogen, hydroxy, C_{1-4} alkoxy, C_{1-4} alkanoyl, carbamoyl, C_{3-7} eycloalkyl (optionally substituted with 1 or 2 hydroxy groups), cyano(C_{1-4})alkyl, aryl, heterocyclyl, C_{1-4} alkyl (optionally substituted with 1 or 2 R^8 -groups), and groups of the formulae B and B'

$$-(CH_2)_t$$
 $(OH)_y$
 $(OH)_y$
 (B)
 (B)

wherein y is 0 or 1, t is 0, 1, 2, or 3 and u is 1 or 2;

provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen;

 \mathbb{R}^3 -is independently selected from hydroxy, \mathbb{C}_{1-4} alkoxy \mathbb{C}_{1-4} alkoxy, hydroxy \mathbb{C}_{1-4} alkoxy, 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof, aryl, heterocyclyl, \mathbb{C}_{3-7} cycloalkyl, \mathbb{C}_{1-4} alkoxy, \mathbb{C}_{1-4} alkoxy, \mathbb{C}_{1-4} alkyl $\mathbb{S}(\mathbb{O})_b$ - (wherein b is 0, 1, or 2), \mathbb{C}_{3-6} cycloalkyl $\mathbb{S}(\mathbb{O})_b$ - (wherein b is 0, 1, or 2), aryl $\mathbb{S}(\mathbb{O})_b$ - (wherein b is 0, 1, or 2), heterocyclyl $\mathbb{S}(\mathbb{O})_b$ - (wherein b is 0, 1, or 2), benzyl $\mathbb{S}(\mathbb{O})_b$ - (wherein b is 0, 1, or 2), -N(OH)CHO, - $\mathbb{C}(\mathbb{S}^3-\mathbb{S}^3)$ - ($\mathbb{S}^3-\mathbb{S}^3$ - $\mathbb{S}^3-\mathbb{S}^3$ - \mathbb{S}^3 - $\mathbb{$

Application No. 10/506,748 Amendment Dated 09/18/2006 Reply to Office Action of 05/22/2006

 $-C(=N-OH)N(C_{3-6}eycloalkyl)_2$, $-COCOOR^9$, $-C(O)N(R^9)(R^{10})$, $-NHC(O)R^9$, $-C(O)NHSO_2(C_{1-4}alkyl)$, $-NHSO_2R^9$, $(R^9)(R^{10})NSO_2$ -, $-COCH_2OR^{11}$, $(R^9)(R^{10})N$ -, and $-COOR^9$; R^9 and R^{10} are independently selected from hydrogen, bydroxy, $C_{1-4}alkyl$ (optionally substituted

 R^{9} -and R^{10} -are independently selected from hydrogen, hydroxy, C_{1-4} alkyl (optionally substituted with 1 or 2 hydroxy groups), eyano(C_{1-4})alkyl, trihalo(C_{1-4})alkyl, aryl, heterocyclyl, and heterocyclyl(C_{1-4} alkyl); or R^{9} -and R^{10} -together with the nitrogen to which they are attached form a 4- to 6-membered ring where the ring is optionally substituted on carbon with 1 or 2 substituents independently selected from exe, hydroxy, carboxy, halo, nitro, cyano, carbonyl, C_{1-4} alkoxy, and heterocyclyl, or the ring may be optionally substituted on two adjacent carbons with -O-CH $_2$ -O- to form a cyclic acetal wherein one or both of the hydrogens of the -O-CH $_2$ -O- group may be replaced by a methyl; R^{13} is selected from hydroxy, halo, trihalomethyl, and C_{1-4} alkoxy; and R^{14} -is independently selected from hydrogen, C_{1-4} alkyl, and hydroxy C_{1-4} alkyl; or a pharmaceutically acceptable salt or prodrug thereof.

17-22. (Cancelled)

23. (Currently amended) A compound of claim 16 selected from:

5-chloro-*N*-[1-(methoxycarbonylmethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1*H*-indole-2-carboxamide;

N-[1-(carboxymethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-5-chloroindole-2-carboxamide; <u>and</u> 5-chloro-*N*-(2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-[{2-oxo-1-[2-oxo-2-(pyridin-2-ylamino)ethyl]-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide;

5-chloro-*N*-{1-[2-(methylthio)ethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide;

5-chloro-*N*-{1-[2-(methylsulphinyl)ethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide:

5-chloro-*N*-{1-[2-(methylsulphonyl)ethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide:

5-chloro-*N*-{2-oxo-1-[2-oxo-2-(1,3,4-thiadiazol-2-ylamino)ethyl]-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(6-methylpyridin-2-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

Application No. 10/506,748 Amendment Dated 09/18/2006 Reply to Office Action of 05/22/2006

5-chloro-*N*-{2-oxo-1-[2-oxo-2-(pyridin-3-ylamino)ethyl]-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroguinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-N-(1-{2-[(4-cyano-1*H*-pyrazol-3-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(4-methyl-1,3-thiazol-2-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(6-chloropyridin-3-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(3-hydroxypyridin-2-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(2-oxo-1-{2-oxo-2-[(pyridin-2-ylmethyl)amino]ethyl}-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-{2-oxo-1-[2-oxo-2-(pyridin-4-ylamino)ethyl]-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(1-methyl-1*H*-pyrazol-5-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(1,3-dimethyl-1*H*-pyrazol-5-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(2-oxo-1-{2-oxo-2-[(pyrazin-2-ylmethyl)amino]ethyl}-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N* (1-{2-[(6-fluoropyridin-3-yl)amino] 2-oxoethyl} 2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(2-hydroxypyrimidin-4-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-{2-oxo-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide:

5-chloro-*N*-(1-{2-[(1-ethyl-1*H*-pyrazol-5-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(2-oxo-1-{2-oxo-2-[(5-oxo-4,5-dihydro-1*H*-pyrazol-3-yl)amino]ethyl}-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

Application No.	10/506,748
Amendment Dated	09/18/2006
Reply to Office Action of	05/22/2006

5-chloro-*N*-(1-{2-[(4-hydroxypyrimidin-2-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(3-methylpyridin-2-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(6-chloropyridazin-3-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl) 1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(1*H*-imidazol-2-ylmethyl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(1-methyl-1*H*-pyrazol-3-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-{2-oxo-1-[2-oxo-2-(2*H*-tetrazol-5-ylamino)ethyl]-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(3-ethyl-1*H*-pyrazol-5-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-(1-{2-[(5-fluoropyridin-2-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

N-(1-{2-[(6-bromopyridin-3-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-5-chloro-1*H*-indole-2-carboxamide;

5-chloro-*N*-[1-(2-hydroxyethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1*H*-indole-2-carboxamide; 5-chloro-*N*-{1-[(2,2-dimethyl-1,3-dioxan-5-yl)methyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide;

5-chloro-*N*-{1-[3-hydroxy-2-(hydroxymethyl)propyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide;

5-chloro-*N*-[1-(2,3-dihydroxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1*H*-indole-2-carboxamide;

5-chloro-*N*-[1-(3-hydroxy-2-oxopropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1*H*-indole-2-carboxamide;

5-chloro-*N*-{1-[(2*R*)-2,3-dihydroxypropyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide:

5-chloro-*N*-(1-{2-[(methylsulfonyl)amino]ethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

N-{1-[2-(acetylamino)ethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl}-5-chloro-1*H*-indole-2-carboxamide;

Application No.	10/506,748
Amendment Dated	09/18/2006
Reply to Office Action of	05/22/2006

5-chloro-*N*-(2-oxo-1-{2-[(trifluoroacetyl)amino]ethyl}-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide;

5-chloro-*N*-[1-(3-hydroxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1*H*-indole-2-carboxamide; *N*-{1-[(2*Z*)-2-amino-2-(hydroxyimino)ethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl}-5-chloro-1*H*-indole-2-carboxamide;

5-chloro-*N*-(6-fluoro-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carboxamide; and 5-chloro-*N*-[6-(methyloxy)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1*H*-indole-2-carboxamide; or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

24. (Previously Presented) A pharmaceutical composition which comprises a compound of claim 16, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, in association with a pharmaceutically acceptable diluent or carrier.

25 – 26. (Cancelled)

27. (Previously Presented) A process for the preparation of a compound claim 16, which process comprises:

reacting an acid of the formula (2)

or an activated derivative thereof; with an amine of formula (3)

and thereafter if necessary

- i) converting a compound of the formula (1) into another compound of the formula (1);
- ii) removing any protecting groups; or
- iii) forming a pharmaceutically acceptable salt or in vivo hydrolysable ester.